We describe here compounds useful in modulating the levels of URIC ACID in the Blood, formulations containing them and Methods for use. The compounds described here are used in the Treatment or prevention of disorders associated with Aberrant levels of URIC ACID.These Disorders include polycythemia, myeloid metaplasia, gout, hyperuricemia, hypertension, coronary heart disease, gallstones and Kidney Failure, among others.Claim 1: a compound of the formula (1), where ra and RB are selected from h, halogen, alkyl of C1 - 6； or ra and RB, together with the carbon Atom to which they are attached, forming a Ring of 3 -, 4 -, 5 - or 6 - member optionally containing one or two heteroatoms selected O, N and S； M is H, alkyl cation C1 - 3 or a pharmaceutically acceptable； x1 is n, CHC (Halogen) or C (c1-4 alkyl is n or CH)； x2, X3 is n, CH, C (Halogen) or C (c1-4 alkyl)； x4 is n or CH, where at least one of X1, X2, X3 and X4 is Y1 is n； n or CR1, CR2 or y2 is n； r1 is H, CF3, CH3, OCH3, F or cl； R2 is H, Methyl, Ethyl, propyl, Isopropyl, Tert Butyl, ciclopropilo, ciclobut ILO, CF3, Oh, OCH3, ethoxy, sh, Sch3, sch2ch3, CH2OH, C (CH3) 2OH, F, CL, CN, COOH, coor2, CONH2,Conhr2 or so2nh2； where R2 is H or alkyl c1-3； R3 is H, halogen, alkyl of C1 - CN, - 6, 6 - alkoxy C1； and R IS h, halogen, alkyl of C1 - CN, - 6, 6 - alkoxy or C1； R3 and R4 with carbon Atoms to which they adhere to form a Ring optionally replaced with 5 or 6 members, which contains Optionally one or two heteroatoms selected from o, N and S,Where the said five or six member Ring may be saturated or unsaturated ring, a Ring of an Aromatic Ring； and given that: if x2 and X4 are both n, then X1 cannot be C (Halogen)； or if x2 and X4 are both n R4, so can't be cl； or if x2 and are Both X4 Y2 n, then can not be C CL； if x1 and x2 are both n,Then X3 can not be c cl； and given that the compound of the formula (1) is not acid, 1 - (3 - (4-cyanophenyl) - 4 - iltio ciclopropanocarbox u00edlico pyridin).В цій заявці описан
